Michael J. Cork

1986–2025 年に発表

118
論文数
20,381
被引用数
72
h 指数
110
i10 指数

被引用数

Michael J. Cork の年別被引用数1964 年: 被引用 1 件1986 年: 被引用 11 件1987 年: 被引用 1 件1993 年: 被引用 3 件1994 年: 被引用 6 件1995 年: 被引用 6 件1996 年: 被引用 20 件1997 年: 被引用 18 件1998 年: 被引用 32 件1999 年: 被引用 20 件2000 年: 被引用 38 件2001 年: 被引用 20 件2002 年: 被引用 31 件2003 年: 被引用 15 件2004 年: 被引用 18 件2005 年: 被引用 12 件2006 年: 被引用 43 件2007 年: 被引用 34 件2008 年: 被引用 44 件2009 年: 被引用 59 件2010 年: 被引用 45 件2011 年: 被引用 80 件2012 年: 被引用 95 件2013 年: 被引用 122 件2014 年: 被引用 107 件2015 年: 被引用 122 件2016 年: 被引用 95 件2017 年: 被引用 154 件2018 年: 被引用 175 件2019 年: 被引用 591 件2020 年: 被引用 763 件2021 年: 被引用 845 件2022 年: 被引用 681 件2023 年: 被引用 679 件2024 年: 被引用 1,047 件2025 年: 被引用 552 件2026 年: 被引用 9 件1965〜1985 年は被引用が無いため表示していません1988〜1992 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,695 件、この内訳の 18.6%イギリス: 引用元論文 832 件、この内訳の 9.1%ドイツ: 引用元論文 713 件、この内訳の 7.8%イタリア: 引用元論文 463 件、この内訳の 5.1%中国: 引用元論文 408 件、この内訳の 4.5%フランス: 引用元論文 391 件、この内訳の 4.3%カナダ: 引用元論文 373 件、この内訳の 4.1%日本: 引用元論文 364 件、この内訳の 4%オランダ: 引用元論文 322 件、この内訳の 3.5%スペイン: 引用元論文 282 件、この内訳の 3.1%スイス: 引用元論文 257 件、この内訳の 2.8%デンマーク: 引用元論文 249 件、この内訳の 2.7%
0%18.6%その他 30.4%

分野

  • Medicine73.4%
  • Immunology and Microbiology13.1%
  • Biochemistry, Genetics and Molecular Biology6.4%
  • Pharmacology, Toxicology and Pharmaceutics2.5%
  • Health Professions1.6%
  • Neuroscience0.8%
  • その他2.2%

トピック

  • Dermatology and Skin Diseases18.6%
  • Allergic Rhinitis and Sensitization8.7%
  • Psoriasis: Treatment and Pathogenesis7.9%
  • Asthma and respiratory diseases6.6%
  • Food Allergy and Anaphylaxis Research3.9%
  • Urticaria and Related Conditions3.1%
  • その他51.2%

共著者

全論文

検索で開く
  1. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2016 被引用: 2,045

  2. Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

    著者: , , , , , , , , , , , , , , , , , , , , , , - British Journal of Dermatology 2020 被引用: 595

  3. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David J. Cohen, David M. Pariser, Elaine C. Siegfried, Eric L. Simpson, Jeffrey Leflein, Jeffrey S. Weinberg, John Browning, Joyce Teng, Lara Wine Lee, Lawrence Sher, Lucia Z. Diaz, Lynda C. Schneider, Mercedes E. González, Ned T. Rupp, Peck Y. Ong, Robert Cartwright, Robert Sidbury, Weily Soong, Andreas Pinter, Andreas Wollenberg, Christina Schnopp, Michael J. Cork, Peter D. Arkwright, Anna Korkosz, Dorota Bystrzanowska, Ewa Sygula, Jacek Zdybski, Kamila Padlewska - The Lancet 2022 被引用: 264

  4. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the European Academy of Dermatology and Venereology 2020 被引用: 465

  5. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the American Academy of Dermatology 2020 被引用: 389

  6. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , - The Lancet 2020 被引用: 491

  7. Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis

    著者: , , , , , , - JID Innovations 2022 被引用: 226

  8. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t

    著者: , , , , , , , , , , , , , , - British Journal of Dermatology 2017 被引用: 475

  9. Conjunctivitis in dupilumab clinical trials

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - British Journal of Dermatology 2019 被引用: 422

  10. Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis

    著者: , , , , , , , , , , , , , , , - JAMA Dermatology 2023 被引用: 137

  11. Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial

    著者: , , , , , , , , , , - British Journal of Dermatology 2023 被引用: 104

  12. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , - The Lancet 2020 被引用: 309

  13. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Cisca Wijmenga, Cordelia Langford, Sarah Edkins, Robert Andrews, Hannah Blackburn, Amy Strange, Gavin Band, Richard D. Pearson, Damjan Vukcevic, Chris C. A. Spencer, Panos Deloukas, Ulrich Mrowietz, Stefan Schreiber, Stephan Weidinger, Sulev Kõks, Külli Kingo, Tõnu Esko, Andres Metspalu, Henry W. Lim, John J. Voorhees, Michael Weichenthal, H.‐Erich Wichmann, Vinod Chandran, Cheryl F. Rosen, Proton Rahman, Dafna D. Gladman, C.E.M. Griffiths, André Reis, Juha Kere, Rajan P. Nair, André Franke, Jonathan N W N Barker, Gonçalo R. Abecasis, James T Elder, Richard C. Trembath - Nature Genetics 2012 被引用: 1,047

  14. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)

    著者: , , , , , , , , , , , , , , , - American Journal of Clinical Dermatology 2022 被引用: 120

  15. Adverse effects of topical glucocorticosteroids

    著者: , , , - Journal of the American Academy of Dermatology 2005 被引用: 1,122

  16. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Suzannah J. Bumpstead, Sarah Hunt, Simon Potter, Sarah Edkins, Cordelia Langford, Leena Peltonen, Panos Deloukas, Juan P. Casas, Michael J. Cork, Rachid Tazi‐Ahnini, Aiden Corvin, Gilean McVean, Alexander Dilthey, Gil McVean, Loukas Moutsianas, Stephen Leslie, Audrey Duncanson, Xavier Estivill, Eva Riveira‐Muñoz, Brian Kirby, Oliver FitzGerald, Emiliano Giardina, Giuseppe Novelli, Wolfgang Weger, Angelika Hofer, Wolfgang Salmhofer, André Reis, Ulrike Hüffmeier, Alan D. Irvine, Janusz Jankowski, Jesús Lascorz, A. David Burden, Joyce Leman, Katarina Wolk, Lotus Mallbris, Mona Ståhle, Hugh S. Markus, W.H. Irwin McLean, Lena Samuelsson, Colin N A Palmer, Carlo Perricone, Robert Plomin, Rotraut Mößner, Åsa Torinsson Naluai, Lena Samuelsson, Heiko Traupe, Carlo Perricone, Robert Plomin, Ramón M. Pujol, Adrian Hayday, Stephen Sawcer, Juha Kere, Catherine Smith, Heiko Traupe - Nature Genetics 2010 被引用: 1,058

  17. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention

    著者: , , , , , , , , , - Journal of Allergy and Clinical Immunology 2014 被引用: 718

  18. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the American Academy of Dermatology 2017 被引用: 236

  19. Epidermal Barrier Dysfunction in Atopic Dermatitis

    著者: , , , , , , , , , - Journal of Investigative Dermatology 2009 被引用: 756

  20. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - British Journal of Dermatology 2018 被引用: 177

  21. Different types of emollient cream exhibit diverse physiological effects on the skin barrier in adults with atopic dermatitis

    著者: , , , , , , , , , , - Clinical and Experimental Dermatology 2022 被引用: 65

  22. Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase II a open‐label trial and subsequent phase III open‐label extension

    著者: , , , , , , , , , , , , , , , , , , , , , - British Journal of Dermatology 2019 被引用: 145

  23. A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy

    著者: , , , , , , , , , , , , , , - Journal of the European Academy of Dermatology and Venereology 2020 被引用: 87

  24. Enhancement of stratum corneum lipid structure improves skin barrier function and protects against irritation in adults with dry, eczema‐prone skin*

    著者: , , , , , , , - British Journal of Dermatology 2021 被引用: 75